Matthew Dunn has extensive experience in biochemistry and molecular biology, in particular nucleic acid and protein engineering and evolution, to develop commercially relevant bioproducts. He leverages computational biology and high throughput screening strategies to accelerate the identification of biomolecules of interest, directly facilitating ArkeaBio’s vaccine development efforts. Matt is also versed in the development of comprehensive IP strategies for early-stage companies, including filing and prosecuting key patent applications for core technology. Matt holds a degree in genetics, cell, and developmental biology and a PhD in molecular and cellular biology from Arizona State University. He completed a brief post-doc at University of California Irvine in the Department of Pharmaceutical Sciences before joining enEvolv (acquired by Zymergen) as a protein engineer developing novel protein sensors for strain engineering. Thereafter, he joined Dropworks (acquired by BioRad) as the Director of Research + Development and Head of IP, where he helped lead the development of a continuous flowing digital PCR system and its reagent portfolio. Matt Dunn is currently the Vice President of Technology + IP at ArkeaBio leading the development of a cost-effective, scalable vaccine-based solution to reduce livestock enteric methane emissions.